Co-crystal of gabapentin, ketoprofen and lysine, pharmaceutical compositions and their medical use
The present invention relates to a new co-crystal of Gabapentin, Ketoprofen and Lysine, to pharmaceutical compositions and to their use in the prevention, reduction or treatment of pain and/or inflammation.
1 . A co-crystal of Gabapentin, Ketoprofen and Lysine wherein the molar ratio of the components is 1:1:1, and wherein the co-crystal is characterized by the following XRPD diffraction peaks: 3.6, 9.5, 9.6, 18.5 and 20.0 degrees 2-theta±0.2 degrees 2-theta.
2 . The co-crystal according to claim 1 , further characterized by the following XRPD diffraction peaks: 15.4, 17.8, 21.0, 21.8 and 24.2 degrees 2-theta±0.2 degrees 2-theta.
3 . The co-crystal according to claim 1 , further characterized by one or more of the following:
a DSC thermogram with the endothermic peak corresponding to the melting point at about 141.4° C. as shown in FIG. 2 ;
a TGA thermogram as shown in FIG. 5 ;
an FT Raman spectrum which exhibits the following absorption bands:
Position (cm −1 )
intensity
272
14.482
290
15.262
350
8.548
373
9.146
410
12.010
507
9.469
618
16.350
711
18.962
723
15.118
759
9.965
783
8.629
820
8.798
884
15.143
912
10.347
976
15.373
1001
116.397
1032
22.031
1056
15.102
1265
15.288
1281
19.151
1315
17.851
1346
12.275
1362
12.462
1396
15.608
1449
40.732
1490
8.848
1598
97.480
1652
58.327
2723
9.298
2771
11.471
2863
55.705
2929
93.607
2967
51.194
3005
21.687
3064
78.264;
an FT-IR spectrum which exhibits the following absorption bands:
Position (cm −1 )
intensity
420
61.320
479
86.959
496
84.511
508
83.197
556
78.060
579
84.959
603
85.297
619
82.829
641
75.429
654
84.715
691
65.138
700
62.820
709
62.038
741
86.760
777
84.071
828
88.929
841
90.789
881
80.755
910
87.977
928
88.449
944
88.718
963
87.854
999
90.389
1028
89.041
1060
86.249
1076
87.549
1089
86.128
1114
90.673
1142
85.854
1158
83.571
1179
85.407
1204
85.563
1243
72.908
1281
63.418
1317
73.752
1359
64.089
1391
54.270
1426
78.288
1450
71.708
1474
67.220
1501
58.164
1508
57.858
1542
63.709
1578
74.234
1596
77.930
1628
69.686
1649
74.257
2600
83.830
2850
79.325
2929
76.320;
a 1 H-NMR spectrum exhibiting the solution 1 H-NMR signals as shown in FIG. 8 ; and
a solid state 13 C CPMAS spectrum exhibiting the 13 C CPMAS signals as shown in FIGS. 9 to 11 .
4 . The co-crystal according to claim 1 , wherein the Ketoprofen is (S)-Ketoprofen.
5 . The co-crystal according to claim 1 , wherein the Lysine is (S)-Lysine.
6 . A method for the prevention, reduction or treatment of pain and/or inflammation in a subject in need thereof, comprising administration of the co-crystal according to claim 1 , alone or in combination with one or more physiologically acceptable excipients.
7 . The method according to claim 6 , wherein the pain is acute or chronic pain.
8 . The method according to claim 6 , wherein the pain is selected from headache, toothache, menstrual pain, muscle pain, neuropathic pain, pain associated to neuroinflammation, diabetic neuropathy, cancer pain, osteoarthritis, low back pain, sciatalgia, fibromyalgia, trigeminal neuralgia, post-surgical and post-operative pain, post herpetic neuralgia, rheumatoid arthritis, ankylosing spondylitis, frozen shoulder, phantom limb pain or HIV pain.
9 . A pharmaceutical composition comprising the co-crystal according to claim 1 and a least one pharmaceutically acceptable excipient.
10 . The pharmaceutical composition according to claim 9 , which contains 0.5-60% by weight of the co-crystal and 40-99.5% by weight of one or more pharmaceutically acceptable excipients.
11 . The pharmaceutical composition according to claim 9 which is a solid composition for oral administration.
12 . The pharmaceutical composition according to claim 10 , which is a solid composition for oral administration.
13 . A process for the preparation of the co-crystal according to claim 1 , which comprises:
a) suspending Gabapentin, Ketoprofen and Lysine in a suitable solvent,
b) dissolving Gabapentin, Ketoprofen and Lysine, optionally by heating the suspension, optionally under stirring, till a clear solution is obtained,
c) subsequently cooling the solution, and
d) optionally adding an anti-solvent.
14 . The process according to claim 13 , wherein the Ketoprofen and Lysine in step a) are in form of a Ketoprofen Lysine salt or a co-crystal.
15 . The process according to claim 13 , wherein the Ketoprofen is the free acid and/or said Lysine is in neutral form.
16 . The process according to claim 13 , wherein the Gabapentin is in neutral form.